AT-752

DRUG3 trials

Sponsors

Atea Pharmaceuticals, Inc.

Conditions

DengueDengue Fever

Phase 1

Study of AT-752 in Healthy Subjects

CompletedNCT04722627

Atea Pharmaceuticals, Inc.Dengue

Start: 2021-03-09End: 2021-11-14Updated: 2022-10-17

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

TerminatedNCT05366439

Atea Pharmaceuticals, Inc.Dengue

Start: 2022-04-22End: 2023-03-16Updated: 2023-04-21

Phase 2

Study of AT-752 in Patients With Dengue Infection

TerminatedNCT05466240

Atea Pharmaceuticals, Inc.Dengue Fever

Start: 2022-04-29End: 2023-01-19Updated: 2024-03-05

Related Papers

Therapeutic Approaches Against Dengue Virus: Current Status of Vaccines, Antivirals, and Monoclonal Antibodies.

2026-06-08

First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus

Antimicrobial Agents and Chemotherapy2024-03-2510 citations